Figure 1.

Peripheral blood immune cell frequencies in patients with AIH before and after 4 months immunosuppression therapy. (A) Gating strategy for definition of immune cell subsets, including CD4, CD8, CD4^‐CD8^‐ (double‐negative) T cells; CD4^posCD25^posCD127^neg regulatory T cells; CD56^pos T cells; NKT; CD19⁺ B cells; CD56^bright NK cells (NK^bright), and CD56^dim NK cells (NK^dim). (B) Cell subset frequencies as a proportion of total lymphocytes at baseline and after 4 months. Wilcoxon test, *P < 0.05, **P < 0.01, ***P < 0.0001. Red dots indicate patients with high starting B cell frequency that declined dramatically with therapy. (C) Ratio of Tregs to NK^bright cells in steroid‐naive, 4‐month follow‐up, and hemochromatosis (control) blood. Wilcoxon test, **P < 0.01; Mann‐Whitney U test, *P < 0.05, ****P < 0.0001. Error bars are means ± SEM. (D) Scatterplot and Spearman's correlation coefficient for the association between changes in ALT levels and NK^bright cell frequencies between baseline and 4 months. Trend line calculated by linear regression is shown.